Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals submitted an investor presentation ahead of investor conferences scheduled for Feb 23-24, 2026. The company reported TTM revenue of INR 8,850 Cr, with mid-to-high teens revenue growth over the last 7 quarters and 16.5% growth in 9M FY26. Margins have expanded significantly — EBITDA margins rose ~90bps to 19.4%, PAT margins improved 250bps to 22.7%, and RoCE increased 200bps to 10.4% in 9M FY26. The company highlighted a strong product pipeline across biologics, NDDS, complex injectables, and ADCs, with key products like Semaglutide (Poviztra®), Bevacizumab, and Lenacapavir. Strategic in-licensing deals with Sanofi and Novo Nordisk, along with expansion into dermatology, consumer health, and super-specialty segments, are driving growth across India, Canada, Europe, and RoW markets.
The presentation reinforces a positive growth narrative with sustained margin expansion and a diversified pipeline, which could support investor confidence. However, this is a routine disclosure of a presentation rather than new material news, so the immediate stock impact is likely limited.